June 14, 2013 | Pathway Genomics wasted no time after the Supreme Court's ruling on drug patents yesterday. Yesterday the company announced that it intends to launch a comprehensive cancer panel next-gen sequencing panel including BRCA1 and BRCA2. They company did not include a date in the announcement. The company (see, Pathway and Me) launched its direct-to-consumer tests in 2009. Press Release